Carnitine plays key roles in mammalian metabolism by enabling the transport of fatty acids into mitochondria as *O*-acyl carnitine esters and in maintaining acetyl group homeostasis.^[@cit1]--[@cit3]^ There is considerable biomedical interest in carnitine and its biosynthesis. Carnitine is biosynthesised from (2*S*)-*N* ^*ε*^-trimethyllysine (TML, (**1**)),^[@cit4]^ which is derived from naturally-occurring TML residues in proteins following proteolysis.^[@cit5]--[@cit7]^ Two 2-oxoglutarate (2OG)-dependent oxygenases, *N* ^*ε*^-trimethyllysine hydroxylase (TMLH) and γ-butyrobetaine hydroxylase (BBOX), catalyse the first and final steps of carnitine biosynthesis, respectively ([Fig. 1](#fig1){ref-type="fig"}).^[@cit8],[@cit9]^ BBOX is one of the proposed targets of Meldonium (Mildronate, THP, Met-88),^[@cit10],[@cit11]^ a drug that is used for treatment of cardiovascular disease^[@cit12]^ and by athletes due to perceived performance-enhancing properties.^[@cit13],[@cit14]^ Carnitine is proposed to promote atherosclerosis by acting as a precursor for trimethylamine oxide.^[@cit15]^ There are also reported links between TMLHE gene mutations and autism in males.^[@cit16]--[@cit18]^ Whilst BBOX has been extensively characterised, including by detailed kinetic and biophysical studies,^[@cit19],[@cit20]^ relatively little is reported on TMLH,^[@cit21]^ notably including on the stereochemistry of the product of its catalysis.

![Carnitine biosynthesis. The first and final steps of [l]{.smallcaps}-carnitine biosynthesis in mammals are catalysed by the 2-oxoglutarate-dependent oxygenases, *N* ^*ε*^-trimethyllysine hydroxylase (TMLH) and γ-butyrobetaine hydroxylase (BBOX).](c6cc08381a-f1){#fig1}

To define the stereochemistry of the TMLH-catalysed 3-hydroxy-*N* ^*ε*^-trimethyllysine (3HO-TML) product (**2**), we investigated the asymmetric synthesis of (2*S*,3*R*)-3HO-TML (**13**) ([Scheme 1](#sch1){ref-type="fig"}). We employed the Dixon methodology,^[@cit22]^ which involves Ag([i]{.smallcaps})-catalysed aldol-type reactions in the presence of a cinchona alkaloid-derived pre-catalyst (**7**).^[@cit22],[@cit23]^ We envisaged this approach could enable the requisite introduction of differently protected *N* ^*α*^- and *N* ^*ε*^-amino groups in a precursor of (**13**). Thus, dibenzyl aldehyde (**6**), prepared in two steps from (**5**), was reacted with *tert*-butyl isocyanoacetate in the presence of Ag~2~O and the pre-catalyst (**7**) to yield *trans*-oxazoline (**8**) (*J* ~2--3~ = 7.0 Hz)^[@cit22],[@cit24]^ in good yield (78%; [Scheme 1](#sch1){ref-type="fig"}).

![Stereoselective synthesis of (2*S*,3*R*)-3-hydroxy-*N* ^*ε*^-trimethyllysine (**13**) and (2*S*,3*R*)-3-hydroxylysine (**11**) *via* oxazoline (**8**). The oxazoline ring hydrolysis and reduction steps can be carried out separately or *via* a one-pot reaction, as displayed.](c6cc08381a-s1){#sch1}

Importantly, high diastereoselectivity favouring the *trans*-diastereomers (2*S*,3*R*/2*R*,3*S* : 2*S*,3*S*/2*R*,3*R*; d.r. \> 95 : 1) of (**8**) was observed (2*S*,3*R* : 2*R*,3*S*; 3 : 1 inferred from analyses on (**9**)). Oxazoline (**8**) was unstable at room temperature (and over prolonged periods at --20 °C), decomposing to give formamide (**9**). We found that conversion of (**8**) to (**9**) is promoted by aqueous citric acid, as reported for other oxazolines,^[@cit22]^ or by aqueous acetic acid in THF in near quantitative yield ([Scheme 1](#sch1){ref-type="fig"}). The stereochemistry of the major stereoisomer of formamide (**9**) was assigned as (2*S*,3*R*) by ^1^H NMR analysis of the corresponding Mosher\'s esters (Fig. S1, ESI[†](#fn1){ref-type="fn"}).^[@cit25],[@cit26]^

(2*S*,3*R*)-3-Hydroxylysine (3HO-Lys) (**11**) was efficiently obtained from (**8**) using H~2~/Pd/C in aqueous citric acid followed by the removal of formamide and *tert*-butyl ester protecting groups *via* acid hydrolysis to give (**11**) ([Scheme 1](#sch1){ref-type="fig"}). The reduction and hydrolysis steps to give (**10**) from (**8**) *via* (**9**) were initially carried out separately; however, use of MeOH/5% citric acid as a solvent during hydrogenation enabled one-pot conversion of (**8**) to (**10**) in high yield (96%). Comparison of the optical rotation of 3HO-Lys (**11**) with that of enantiopure (2*S*,3*R*)-3HO-TML^[@cit24],[@cit27]^ implied an e.r. for (**11**) as ∼3 : 1, consistent with the stereoselectivity observed during oxazoline (**8**) formation.

3HO-TML (**13**) was then synthesised from (**8**) *via* initial hydrogenation in acidic solvent to give the *N* ^*ε*^-amine (**10**). Following treatment with methyl iodide to give (**12**), acid promoted hydrolysis yielded (**13**) with an e.r. of 3 : 1 in favour of (2*S*,3*R*)-3HO-TML ([Scheme 1](#sch1){ref-type="fig"}, (**13**)), as determined by Mosher\'s analysis of the corresponding amide (Fig. S2, ESI[†](#fn1){ref-type="fn"}).

We then investigated the stereochemistry of the TMLH-catalysed product (**2**) using recombinant TMLH^[@cit28]^ and synthetic (2*S*,3*R*)-3HO-TML (**13**) as a standard for comparison by NMR and amino acid analysis. (2*S*)-*N* ^*ε*^-Trimethyllysine (**1**) was converted to 3-hydroxy-*N* ^*ε*^-trimethyllysine (**2**), as shown by 1D and 2D NMR analyses ([Fig. 2A](#fig2){ref-type="fig"} and Fig. S3A--F, ESI[†](#fn1){ref-type="fn"}). Addition of the synthetic (2*S*,3*R*)-3HO-TML standard (**13**) to the TMLH reaction mixture led to the appearance of non-redundant peaks, implying the TMLH-catalysed product to be the (2*S*,3*S*)-stereoisomer (**14**) (assuming retention of the (2*S*)-stereochemistry in the TML substrate; [Fig. 2C](#fig2){ref-type="fig"} and Fig. S3C, ESI[†](#fn1){ref-type="fn"}). This assignment was validated by amino acid analysis, using derivatisation with 6-aminoquinolyl-*N*-hydroxysuccinimidyl carbamate. The enzyme-catalysed product and synthetic standard have identical masses (observed *m*/*z* = 375.2114), but were clearly separated by ultra performance liquid chromatography (UPLC). These results reveal exclusive (\>95%) formation of the (2*S*,3*S*)-stereoisomer (**14**) as the TMLH-catalysed product ([Fig. 2B](#fig2){ref-type="fig"} and Fig. S4, ESI[†](#fn1){ref-type="fn"}).

![TMLH catalysis produces (2*S*,3*S*)-3-hydroxy-*N* ^*ε*^-trimethyllysine (**14**). (A) ^1^H NMR assignment of the product resulting from TMLH-catalysed C-3 hydroxylation of (2*S*)-*N* ^*ε*^-trimethyllysine (**1**). Superimposition of ^1^H NMR spectra of the reaction mixture before (blue) and after (red) addition of TMLH shows 3HO-TML formation. Signals arising between *δ* = 3.5--3.75 ppm (including glycerol) are omitted for clarity. (B) Overlaid extracted ion chromatograms (*m*/*z* = 375.2, corresponding to the mass of derivatised 3HO-TML) for (i) TML incubated with (red) or without (black; at baseline) TMLH and (ii) TMLH-treated TML (red) and TMLH-treated TML spiked with synthetic (2*S*,3*R*)-3HO-TML ((**13**), black). (C) The stereochemistry of TMLH- and BBOX-catalysed hydroxylation is the same relative to the quaternary ammonium and carboxylate groups.](c6cc08381a-f2){#fig2}

The overall results define the stereochemical outcome of the TMLH-catalysed hydroxylation of TML as (2*S*,3*S*)-3-hydroxy-*N* ^*ε*^-trimethyllysine (**14**). Interestingly, BBOX catalyses hydroxylation of γ-butyrobetaine (**3**) to give carnitine (**4**) with the (3*R*)-stereochemistry ([Fig. 1](#fig1){ref-type="fig"}). Thus, the stereochemical outcomes of TMLH and BBOX catalysis are the same relative to the trimethylammonium and carboxylic acid groups ([Fig. 2C](#fig2){ref-type="fig"}), reflecting the likely common evolutionary origins of TMLH and BBOX, as revealed by structural analyses.^[@cit19],[@cit29],[@cit30]^

The results also highlight the continued important role of synthesis, including *via* efficient asymmetric catalysis, for biomolecular structural assignments. Modern proteomic and other mass spectrometry (MS) methodologies are identifying many new potential post-translational modifications (*e.g.* JMJD4-catalysed formation of C-4 hydroxylysine),^[@cit31],[@cit32]^ the regio- and stereochemistries of which need to be confirmed, *e.g.* by NMR, high resolution MS analyses and, at least in our view, wherever possible by comparison with synthetic standards.
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[^1]: †Electronic supplementary information (ESI) available: Synthesis procedures, assay conditions, NMR assignments and spectra, and MS analyses. See DOI: [10.1039/c6cc08381a](10.1039/c6cc08381a) Click here for additional data file.
